Novel Agent for Chronic GVHD Wins FDA Approval

Published Date: 19 Aug 2024

Axatilimab achieved a 75% response rate in patients with previously treated chronic GVHD

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survivors of childhood brain cancer are more likely to be held back in school

2.

According to research, the mineralization of the bone matrix controls the growth of tumor cells.

3.

Video: Liver transplant for patients with advanced colorectal cancer

4.

Specific suicidal patterns mark the highest risk.

5.

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot